Study of Inhaled RNS60 in Combination With Budesonide to Treat Mild to Moderate Asthma

Inclusion Criteria: * Male or female non-smokers, aged between 18 and 65 years. * Clinical diagnosis of mild to moderate asthma meeting NHLBI 2007 guidelines as outlined in Appendix A. * Subjects who have a currently prescribed inhaled corticosteroid medication to treat asthma, alone or in combination with other medications, with usage of 1 month (≥ 95% compliance) or more on the inhaled corticosteroid treatment. * Normal 12-lead ECG at Screening. * Normal single view chest x-ray at Screening. * Men and women of reproductive potential who commit to use adequate contraception during the study and for 1 month following the last day of treatment (Day 57). * Women of childbearing potential who have a negative pregnancy test (serum HCG) at the time of study entry, and again on Day 22. * Subjects, or their legal guardians, must be capable of understanding the purpose and risks of the study and provide written, voluntary, informed consent. Exclusion Criteria: * Chronic or acute disease that might interfere with the evaluation of RNS60. * Pregnancy, intent to become pregnant, or breastfeeding. * Current or prior malignancies (excluding non-melanoma skin carcinoma or in situ carcinoma of the cervix that has been adequately treated). * Positive viral serology test for Human Immunodeficiency Virus (HIV-1), HBsAG and Hepatitis C antibody. * Positive urine drug screen (UDS) for drugs of abuse including alcohol and cotinine at the time of study entry and again on Day 22. * Infections that require intravenous antibiotic therapy. * Significant organ dysfunction, including cardiac, renal, liver, central nervous system, pulmonary, vascular, gastrointestinal, endocrine, or metabolic (e.g., creatinine ≥ 1.6 mg/dL; ALT or AST ≥ 1.5x the upper limit of normal), history of myocardial infarction, congestive heart failure, or arrhythmias within 6 months prior to study entry. * Treatment with a humanized or chimeric antibody therapy within 4 weeks prior to study entry. * Treatment with any investigational drugs, therapies, or medical devices within 4 weeks prior to study entry. * Any use of antidepressants or other psychiatric medicine within 4 weeks prior to study entry and/or during the study treatment period. * Use of any over-the-counter asthma treatments, including Primatene Mist, during the 8-week active study period.